Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer.
Khakoo S, Carter PD, Brown G, Valeri N, Picchia S, Bali MA, Shaikh R, Jones T, Begum R, Rana I, Wotherspoon A, Terlizzo M, von Loga K, Kalaitzaki E, Saffery C, Watkins D, Tait D, Chau I, Starling N, Hubank M, Cunningham D. Khakoo S, et al. Among authors: kalaitzaki e. Clin Cancer Res. 2020 Jan 1;26(1):183-192. doi: 10.1158/1078-0432.CCR-19-1996. Epub 2019 Dec 18. Clin Cancer Res. 2020. PMID: 31852830
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F, Brown G, Cunningham D, Rao S, Tekkis P, Tait D, Morano F, Baratelli C, Kalaitzaki E, Rasheed S, Watkins D, Starling N, Wotherspoon A, Chau I. Sclafani F, et al. Among authors: kalaitzaki e. Oncologist. 2017 Jun;22(6):728-736. doi: 10.1634/theoncologist.2016-0396. Epub 2017 May 5. Oncologist. 2017. PMID: 28476941 Free PMC article. Clinical Trial.
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
Khan K, Rata M, Cunningham D, Koh DM, Tunariu N, Hahne JC, Vlachogiannis G, Hedayat S, Marchetti S, Lampis A, Damavandi MD, Lote H, Rana I, Williams A, Eccles SA, Fontana E, Collins D, Eltahir Z, Rao S, Watkins D, Starling N, Thomas J, Kalaitzaki E, Fotiadis N, Begum R, Bali M, Rugge M, Temple E, Fassan M, Chau I, Braconi C, Valeri N. Khan K, et al. Among authors: kalaitzaki e. Gut. 2018 Aug;67(8):1484-1492. doi: 10.1136/gutjnl-2017-314178. Epub 2017 Aug 8. Gut. 2018. PMID: 28790159 Free PMC article. Clinical Trial.
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer.
Sclafani F, Chau I, Cunningham D, Hahne JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E, De Castro DG, Wotherspoon A, Capdevila J, Glimelius B, Tarazona N, Begum R, Lote H, Hulkki Wilson S, Mentrasti G, Brown G, Tait D, Oates J, Valeri N. Sclafani F, et al. Among authors: kalaitzaki e. Sci Rep. 2018 Jan 23;8(1):1445. doi: 10.1038/s41598-018-19212-5. Sci Rep. 2018. PMID: 29362371 Free PMC article. Clinical Trial.
Neoadjuvant rectal score: run with the hare and hunt with the hounds.
Sclafani F, Kalaitzaki E, Cunningham D, Tait D, Brown G, Chau I. Sclafani F, et al. Among authors: kalaitzaki e. Ann Oncol. 2018 Nov 1;29(11):2261-2262. doi: 10.1093/annonc/mdy403. Ann Oncol. 2018. PMID: 30204839 Free PMC article. No abstract available.
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.
Davidson M, Cafferkey C, Goode EF, Kouvelakis K, Hughes D, Reguera P, Kalaitzaki E, Peckitt C, Rao S, Watkins D, Chau I, Cunningham D, Starling N. Davidson M, et al. Among authors: kalaitzaki e. Clin Colorectal Cancer. 2018 Sep;17(3):223-230. doi: 10.1016/j.clcc.2018.05.014. Epub 2018 Jun 8. Clin Colorectal Cancer. 2018. PMID: 29980492
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
Khan K, Rane JK, Cunningham D, Rao S, Watkins D, Starling N, Kalaitzaki E, Forster M, Braconi C, Valeri N, Gerlinger M, Chau I. Khan K, et al. Among authors: kalaitzaki e. Clin Colorectal Cancer. 2019 Mar;18(1):64-71.e1. doi: 10.1016/j.clcc.2018.09.010. Epub 2018 Sep 29. Clin Colorectal Cancer. 2019. PMID: 30404764
Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients.
Sclafani F, Wilson SH, Cunningham D, Gonzalez De Castro D, Kalaitzaki E, Begum R, Wotherspoon A, Capdevila J, Glimelius B, Roselló S, Thomas J, Tait D, Brown G, Oates J, Chau I. Sclafani F, et al. Among authors: kalaitzaki e. Int J Cancer. 2020 Jan 1;146(1):94-102. doi: 10.1002/ijc.32507. Epub 2019 Jul 5. Int J Cancer. 2020. PMID: 31199501 Free article. Clinical Trial.
Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.
Khan K, Athauda A, Aitken K, Cunningham D, Watkins D, Starling N, Cook GJ, Kalaitzaki E, Chau I, Rao S. Khan K, et al. Among authors: kalaitzaki e. Oncologist. 2016 Dec;21(12):1502-1508. doi: 10.1634/theoncologist.2016-0222. Epub 2016 Oct 14. Oncologist. 2016. PMID: 27742904 Free PMC article.
33 results